FAM
BCRX icon

Fortaleza Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Fortaleza Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,412
Closed -$141K – 196
2015
Q3 		$141K Sell
12,412
-4,535
-27% -$60.5K 0.1% 126
2015
Q2 		$253K Buy
16,947
+3,165
+23% +$36K 0.15% 120
2015
Q1 		$124K Sell
13,782
-20,493
-60% -$212K 0.07% 158
2014
Q4 		$417K Buy
+34,275
New +$379K 0.19% 147

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fortaleza Asset Management's BCRX Position: Q4 2015 in Review

Fortaleza Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2015, closing a stake of 12,412 shares — an estimated $141K sold.

Fortaleza Asset Management first reported a position in BCRX in Q4 2014 and held it in 4 quarters. The position peaked at $417K in Q4 2014. 118 funds tracked by Wall St. Rank hold BCRX as of Q4 2015.

  • Fortaleza Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Fortaleza Asset Management sold 12,412 BioCryst Pharmaceuticals shares in Q4 2015, an estimated $141K.
  • Fortaleza Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • Fortaleza Asset Management's BioCryst Pharmaceuticals position peaked at $417K in Q4 2014.
  • 118 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2015.

Based on Fortaleza Asset Management's 13F filing for Q4 2015, filed 26 Jan 2016.